Brian Daniels

Brian Daniels, MD, joined 5AM Ventures as a Venture Partner in 2014 and transitioned to Partner in 2018. Dr. Daniels previously spent over two decades in clinical drug development, including leading the Development and Medical Affairs at Bristol-Myers Squibb for the last ten years. He directed the development of numerous innovative medicines that have contributed to the improvement of patients across a range of serious diseases. These include ORENCIA and NULOJIX in immunology/transplant, REYATAZ, DAKLINZA and BARACLUDE in virology, ONGLYZA, FARXIGA and MYALEPT in metabolic, ELIQUIS in CV and YERVOY, OPDIVO, SPRYCEL and IXEMPRA in oncology. Dr. Daniels is currently a Director at these 5AM companies: Cabaletta Bio and Artiva. He is on the Scientific Advisory Boards for Soteria and Ideaya Biosciences (NASDAQ: IDYA). Dr. Daniels received B.S. and MS degrees from MIT and his MD from Washington University in St. Louis. He trained in internal medicine at New York Hospital and Rheumatology/Immunology at UCSF. Dr. Daniels is based in the San Francisco office.